Home Cytoskeletal Signaling Kinesin Inhibitor VLS-1488(KIF18A-IN-6 )

research use only

VLS-1488(KIF18A-IN-6 ) Kinesin Inhibitor

Cat.No.: E4602

VLS-1488 (KIF18A-IN-6) is an oral inhibitor of KIF18A with an IC50 of 0.016 μM. KIF18A is a mitotic kinesin motor protein that localizes at the plus-end of kinetochore microtubule spindle fibres and is crucial for cell division in aneuploid cancer cells with high chromosomal instability (CIN).
VLS-1488(KIF18A-IN-6 ) Kinesin Inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 559.74

Jump to

Quality Control

Batch: E460202 DMSO]100 mg/mL]false]Ethanol]5 mg/mL]false]Water]Insoluble]false Purity: 98.50%
98.50

Chemical Information, Storage & Stability

Molecular Weight 559.74 Formula

C28H37N3O5S2

 Storage (From the date of receipt)
CAS No. 2914879-10-8 Download SDF Storage of Stock Solutions

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (178.65 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 5 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
KIF18A
0.016 μM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-11-04)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05902988 RECRUITING
Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer; Triple Negative Breast Cancer; Head and Neck Squamous Cell Carcinoma; Ovarian Carcinosarcoma; Uterine Carcinosarcoma; Uterine Serous Carcinoma; Endometrium Cancer; Chromosomal Instability
Volastra Therapeutics, Inc.
 2023-10-18 PHASE1; PHASE2